Search
Tedizolid phosphate
go.drugbank.com/drugs/DB09042Approved[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Alosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnAlosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured … In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitThere have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.
Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acidBemiparin
go.drugbank.com/drugs/DB09258ApprovedInvestigationalWithdrawnBemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). … Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class [A7866].
Categories: Heparin (Low Molecular Weight)Gepirone
go.drugbank.com/drugs/DB12184Approved[A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder. … It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Carprofen
go.drugbank.com/drugs/DB00821ApprovedVet approvedWithdrawnIt is no longer marketed for human usage, after being withdrawn on commercial grounds. … Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide … [L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331]
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma … [A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients
Synonyms: 4-amino-N(10)-methylpteroylglutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acidPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.